JP2018530574A5 - - Google Patents

Download PDF

Info

Publication number
JP2018530574A5
JP2018530574A5 JP2018518654A JP2018518654A JP2018530574A5 JP 2018530574 A5 JP2018530574 A5 JP 2018530574A5 JP 2018518654 A JP2018518654 A JP 2018518654A JP 2018518654 A JP2018518654 A JP 2018518654A JP 2018530574 A5 JP2018530574 A5 JP 2018530574A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antibody
composition according
antigen
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018518654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018530574A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/055794 external-priority patent/WO2017062649A1/en
Publication of JP2018530574A publication Critical patent/JP2018530574A/ja
Publication of JP2018530574A5 publication Critical patent/JP2018530574A5/ja
Pending legal-status Critical Current

Links

JP2018518654A 2015-10-07 2016-10-06 患者の加齢黄斑変性を治療する方法 Pending JP2018530574A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562238483P 2015-10-07 2015-10-07
US62/238,483 2015-10-07
PCT/US2016/055794 WO2017062649A1 (en) 2015-10-07 2016-10-06 A method for treating age-related macular degeneration in a patient

Publications (2)

Publication Number Publication Date
JP2018530574A JP2018530574A (ja) 2018-10-18
JP2018530574A5 true JP2018530574A5 (https=) 2019-11-14

Family

ID=57200105

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018518654A Pending JP2018530574A (ja) 2015-10-07 2016-10-06 患者の加齢黄斑変性を治療する方法

Country Status (4)

Country Link
US (1) US11203634B2 (https=)
EP (1) EP3359566A1 (https=)
JP (1) JP2018530574A (https=)
WO (1) WO2017062649A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2984352T3 (es) 2016-06-14 2024-10-29 Regeneron Pharma Anticuerpos anti-C5 y usos de los mismos
MA51147A (fr) 2017-12-13 2021-03-24 Regeneron Pharma Associations d'anticorps anti-c5 et utilisations associées
US20190247560A1 (en) 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
CN113754763B (zh) * 2020-06-05 2024-03-08 天辰生物医药(苏州)有限公司 分离的抗原结合蛋白及其用途
EP4397306A1 (en) * 2023-01-05 2024-07-10 Dompe' Farmaceutici S.P.A. C5ar1 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid
AU2024271004A1 (en) * 2023-05-16 2026-01-15 Regenxbio Inc. Vectorized anti-complement antibodies and administration thereof
TW202525324A (zh) * 2023-08-17 2025-07-01 大陸商信達生物製藥（蘇州）有限公司 治療年齡相關性黃斑變性和糖尿病性黃斑水腫的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
EP1413587A2 (en) 1991-05-03 2004-04-28 Washington University Modified complement system regulator
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CZ302070B6 (cs) 1998-04-21 2010-09-29 Micromet Ag Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US8454963B2 (en) 2003-11-13 2013-06-04 Musc Foundation For Research Development Tissue targeted complement modulators
EP3479844B1 (en) 2005-04-15 2023-11-22 MacroGenics, Inc. Covalent diabodies and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20130108481A (ko) 2005-08-19 2013-10-02 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
BRPI0620316A2 (pt) 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos
PL3167888T3 (pl) 2006-03-15 2024-08-26 Alexion Pharmaceuticals, Inc. Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
EP2824111B1 (en) * 2010-04-30 2017-03-22 Alexion Pharmaceuticals, Inc. Anti-C5A Antibodies and Methods for Using the Antibodies
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
TWI588156B (zh) 2011-03-28 2017-06-21 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics

Similar Documents

Publication Publication Date Title
JP2018530574A5 (https=)
AU2025271125A1 (en) Methods for treating or preventing ophthalmological conditions
JP2025004075A (ja) 眼疾患を処置する方法
ES2968255T3 (es) Anticuerpos anti-péptidos beta amiloides N3-beta-glu y usos de los mismos
JP2016528247A5 (https=)
TWI848905B (zh) 用於治療補體介導之疾病及病症之方法
JP2017042172A5 (https=)
JP2010528047A5 (https=)
JP2017515811A5 (https=)
RU2009147744A (ru) Профилактика и лечение патологических состояний глаз, вызванных комплементом
JP2011504872A5 (https=)
EA201000787A1 (ru) Антигенсвязывающие белки
JP2015503909A5 (https=)
JP2018505882A5 (https=)
RU2018119014A (ru) АНТИТЕЛА ПРОТИВ Нtr1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2019510078A5 (https=)
US20240052038A1 (en) Modified anti-PD-L1 Antibody and Methods and Uses for Treating a Neurodegenerative Disease
JP2018529661A5 (https=)
JP2018512402A5 (https=)
JP2009519025A5 (https=)
ES2855973T3 (es) Nuevo anticuerpo útil en trastornos neurológicos o neurodegenerativos
JP2011503094A5 (https=)
TW202523689A (zh) 治療脊髓損傷及疼痛之方法
EP4251204A1 (en) Vegf antagonist for use in methods for treating ocular diseases
ES2985731T3 (es) Tratamiento de exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica mediante antagonismo de IL-20R